The goal of the current investigation was to examine a cohort of symptomatic and asymptomatic LRRK2 mutation carriers, in order to address whether the reported alterations in amyloid ␤ (A␤) and tau species in the CSF of patients with sporadic Parkinson disease (PD) are a part of PD pathogenesis, the aging process, or a comorbid disease in patients with PD, and to explore the possibility of A␤ and tau as markers of early or presymptomatic PD.
clinical phenotype similar to sporadic PD. 8, 9 LRRK2 mutation carriers have been extensively characterized by PET studies, demonstrating neurochemical changes similar to sporadic PD cases, as well as detectable dopaminergic dysfunction in asymptomatic carriers. 10, 11 Thus, subjects with LRRK2 mutations constitute an excellent cohort for studying preclinical and early PD.
In the present study, we examined CSF A␤1-42 (A␤ 42 ) peptide, total tau (t-tau), and phosphorylated tau (p-tau) in symptomatic and asymptomatic LRRK2 mutation carriers. CSF protein levels were correlated with dopamine de-nervation (assessed by PET measurements), to determine whether A␤ 42 and tau species are altered during early PD processes, and to explore the utility of these proteins as early or presymptomatic PD diagnostic or progression markers. METHODS Subjects. This study focused on preclinical and asymptomatic LRRK2 mutation carriers: 18 of the 26 carriers included in the study were asymptomatic at the time of evaluation. The remaining 8 subjects had clinically confirmed PD; most of them were at early disease stages that permitted longrange travel and limited confounding due to complicated CNS changes associated with advanced PD. Details on subject recruitment can be found in the e-Methods on the Neurology ® Web site at www.neurology.org. Demographic and clinical information is listed in table 1 for all subjects. Standard protocol approvals, registrations, and patient consents. This study was approved by the institutional review boards of all participating institutions. All individuals provided written informed consent to participate.
PET, CSF samples, and Luminex assays.
Within 1 year of CSF sample collection, each subject was scanned with 3 tracers, 18 F-6-fluoro-L-dopa (FD, a marker for the uptake and decarboxylation of levodopa as well as the trapping of dopamine in synaptic vesicles), 11 C-(Ϯ)-␣-dihydrotetrabenazine (DTBZ, a vesicular monoamine transporter 2 [VMAT2] ligand), and 11 C-d-threomethylphenidate (MP, a dopamine transporter [DAT] ligand). CSF A␤ 42 , t-tau, and p-tau levels of all cases were measured as previously described. 2 To minimize any age effects, PET data were normalized to age-matched control values. Details can be found in the e-Methods.
Statistical analysis.
All analyses were performed with PASW Statistics 18.0 (SPSS Inc., Chicago, IL). Nonparametric correlation methods (Kendall rank correlation) were used to assess the relationship between the skewed PET measurements and the CSF biomarkers and to minimize the effects of outliers. See more details in the e-Methods. (figure 1 and table 1) . Among asymptomatic muta-tion carriers, 4 subjects had significantly reduced values for all 3 tracers; in subject 1,523, PET abnormalities demonstrated asymmetry, typical of sporadic PD. Subject 1,542 had significantly reduced MP (DAT) binding and FD uptake values only. In subject 1,526, DAT binding was significantly reduced; reduced DTBZ (VMAT2) binding was observed only in the right putamen. Subjects 1,454 and 2,246 showed borderline decrease in right putaminal FD uptake and DAT binding, respectively. All other asymptomatic mutation carriers demonstrated normal uptake/binding of all 3 tracers in the putamen. Subjects 1,465 and 1,543 showed abnormal VMAT2 and DAT binding in the caudate, but not the putamen. Subject 1,457 could not complete the FD scan.
RESULTS
Correlation of CSF biomarkers with PET data. Blood contamination of CSF, which occasionally occurs during lumbar puncture collection, can significantly affect CSF levels of A␤ 42 (but not t-tau or p-tau). 2 To control for this variable, 3 subjects (1 LRRK2 PD and 2 asymptomatic) whose CSF hemoglobin levels were Ͼ250 ng/mL were excluded from further analysis of A␤ 42 .
Similar to our previous report in patients with sporadic PD, 2 CSF levels of all analytes were lower in symptomatic LRRK2 mutation carriers compared to asymptomatic carriers (symptomatic [mean Ϯ SD]: A␤ 42 , 504.1 Ϯ 128.5 pg/mL, t-tau, 24.4 Ϯ 22.6 pg/mL, p-tau, 16.7 Ϯ 3.8 pg/mL; asymptomatic: A␤ 42 , 601.5 Ϯ 234.1 pg/mL, t-tau, 36.4 Ϯ 32.0 pg/mL, p-tau, 21.1 Ϯ 9.0 pg/mL; individual values can be found in table e-1); but this trend did not reach significance, likely due to the limited number of subjects included. Additionally, because symptomatic subjects were older than asymptomatic carriers (mean 67.1 Ϯ 9.8 vs 51.3 Ϯ 12.3 years), the extent of decrease in CSF tau levels in LRRK2 PD may have also been reduced by the known agedependent increase in CSF tau levels (A␤ 42 is stable as a function of age in healthy controls). 2 Nonetheless, the correlations between CSF analyte levels and PET measurements are unlikely to be substantially affected by age because all the PET data were standardized to age-matched control values.
CSF levels of A␤ 42 in the entire LRRK2 cohort decreased with decreasing uptake of FD (Kendall tau ϭ 0.316, p ϭ 0.040), indicating that decreasing protein levels correspond with progressive loss of dopamine function ( figure 2A ). Decreased levels of A␤ 42 also corresponded to lower values of the other PET tracers, as did decreased levels of t-tau or p-tau with all PET tracers, but these relationships did not reach significance (figure 2).
Because LRRK2 mutations are heterogeneous, this analysis was repeated using the subset of patients with the G2019S mutation (n ϭ 11), the most common variant in our cohort. Remarkably, there was a clear reduction in the levels of all proteins with decreasing PET measurements in the striatum, regardless of the tracer used ( figure 3 ). CSF levels of A␤ 42 and p-tau were both reduced with greater degrees of reduced FD uptake (i.e., diminished dopamine function; A␤ 42 : Kendall tau ϭ 0.556, p ϭ 0.025; p-tau: Kendall tau ϭ 0.597, p ϭ 0.020). In addition, reduced CSF p-tau significantly correlated with reduced DTBZ binding (Kendall tau ϭ 0.597, p ϭ 0.013) and MP binding (Kendall tau ϭ 0.559, p ϭ 0.020), but t-tau only significantly correlated with MP binding (Kendall tau ϭ 0.506, p ϭ 0.037). One symptomatic LRRK2 PD subject (1,544) with normal PET measurements demonstrated relatively lowered t-tau and p-tau levels, i.e., behaved more like a patient with PD than a normal control, suggesting that CSF tau might be a more sensitive indicator than the PET measurements.
DISCUSSION Several independent investigations reported that CSF A␤ levels decreased (but not as substantially as in Alzheimer disease [AD]) in pa- tients with sporadic PD, particularly in those with cognitive impairment. 2, 5, 6, 12, 13 Additionally, studies with large cohorts (Ն50 subjects in either sporadic PD or control group) suggest that, unlike what is typically described for AD, tau levels tend to decrease in PD compared to controls. [2] [3] [4] 6 The obvious trend of decreasing CSF levels of A␤ 42 and tau in LRRK2 PD and asymptomatic carriers ( figure 2 and 3 , table e-1) is in line with these observations. This raises the question of whether decreased concentrations of CSF tau and A␤ might be mechanistically involved in PD pathology. Tau pathology and amyloid plaques, though increasingly reported, 14, 15 are not typically seen in the brains of patients with PD. Therefore, it is possible that the decrease in CSF tau and A␤ levels occurs as soluble tau/p-tau and A␤ oligomers, often considered more toxic, 16 deposit in the brains of patients with PD without formation of amyloid plaques and neurofibrillary (tau) tangles.
Regardless of the cause of decreased CSF A␤ 42 , t-tau, and p-tau in asymptomatic and symptomatic mutation carriers, our data suggest that metabolism of A␤ and tau in brain is likely dysfunctional in LRRK2-related PD, even before motor symptoms appear. If the same is true of sporadic PD, then tau and amyloid pathology in patients with PD, rather than just indicating comorbidity or general aging pro- cesses, might interact with synucleinopathy as a pathologic network that contributes to PD development and progression, even at premotor stages. In addition to experiments showing that both tau and A␤ might directly interact with ␣-synuclein, facilitating its aggregation, 17, 18 this argument is further supported by recent independent genome-wide association studies indicating that the SNCA and MAPT genes/regions (encoding ␣-synuclein and tau, respectively) are consistently associated with an increased risk of developing PD. 19, 20 Our results, if applicable to sporadic PD, also suggest that A␤ 42 and tau could potentially be used as biomarkers for early PD diagnosis. However, since they are not particularly strong predictors of the disease condition, it is likely that a combination of A␤ 42 and tau with other markers will be necessary for effective preclinical diagnosis or monitoring disease progression. A major limitation in focusing on LRRK2 mutation carriers is that this approach is logistically difficult in that it requires recruitment from a very limited pool of subjects, lengthy and potentially uncomfortable procedures (PET imaging and lumbar puncture), and in many instances, international travel. Thus, we were only able to study a modest number of participants, and because this was an exploratory study we did not perform statistical correction for multiple comparisons. Therefore, the data need to be interpreted with caution and the results should be replicated, ideally using a longitudinal design with serial PET scans and CSF measurements.
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